Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.

The South Korean biopharma sector is adopting new approaches to beef up original R&D including open innovation, with Hanmi and LegoChem both recently setting up new operations to pursue collaborations as they look to expand internationally.

Following the successful launch of pharma development funds in the past few years, South Korea's health ministry is planning to create a new fund this year to further support domestic pharma firms' efforts to enter overseas markets and spur private sector investment in the broader healthcare industry.